On Monday, the German healthcare and technology group Merck KGaA $MRK announced that it has initiated preliminary discussions to acquire the American company SpringWorks Therapeutics $SWTX, a biotech firm specializing in the development of drugs for cancer and rare diseases. Although no legally binding agreement has been signed yet, this potential acquisition signals a renewed momentum in the healthcare sector after a period of subdued merger and acquisition activities in 2024.